REG - GENinCode PLC - Additional Subscription

GenincodeAnnouncement

06/02/2026 14:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260206:nRSF1144Sa&default-theme=true

RNS Number : 1144S  GENinCode PLC  06 February 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND,
CANADA, REPUBLIC OF SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR
ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT
CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE
SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR
CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY
PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN
GENINCODE PLC OR ANY OTHER ENTITY IN ANY JURISDICTION WHERE TO DO SO WOULD
BREACH ANY APPLICABLE LAW OR REGULATION. NEITHER THIS ANNOUNCEMENT NOR THE
FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN
CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF GENINCODE PLC.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET
ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS
(AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED
IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF
SUCH INSIDE INFORMATION, AS PERMITTED BY MAR. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE
INFORMATION.

 

GENinCode Plc

("GENinCode" or the "Company")

 

Additional Subscription

 

GENinCode (AIM: GENI), the predictive genetics company focused on the
prevention of cardiovascular disease and ovarian cancer, is pleased to
announce that further to the Fundraising initially announced on 21 January
2026, it has received addition interest from investors.

 

The board consider that it would be materially beneficial to the Company and
shareholders to have the additional funding and secure a longer cash runway
for the business as it works to provide the FDA with the necessary updates for
its De Novo application for its CARDIO inCode-Score test.

 

It has therefore agreed to an additional element of the Fundraise to include a
subscription (the "Additional Subscription") for a further 58,000,000 New
Ordinary Shares at the Issue Price of 1 pence per share ("Additional
Subscription Shares"), raising further gross proceeds of £580,000.  The
terms of the Additional Subscription are materially the same as those in the
Fundraising, including price, conditions and admission, which will be on 11
February 2026. While the demand was materially greater than this level, the
Company was limited by its authorities, with the Additional Subscription
Shares being issued using the additional authority set out in the Resolutions
proposed at the General Meeting and the authority granted to the directors at
the annual general meeting of the Company on 30 June 2025.

 

Accordingly, conditional on the passing of the Resolutions at the General
Meeting, the Company has raised total gross proceeds of approximately £4.7
million in aggregate by way of the Fundraising.

 

 

Terms used but not defined in this announcement have the same meaning as set
out in the Company's announcement released on 21 January 2026 save that the
definition of Fundraise shall include the Additional Subscription.

For further information, please contact:

 

 GENinCode Plc                                                           www.genincode.com (http://www.genincode.com)   or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited (Nomad, Broker and Joint Bookrunner)  Tel: +44 (0) 20 7220 0500
 Giles Balleny / Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Sciences Specialist Sales)

 Harriet Ward (Corporate Broking)

 Dale Bellis / Michael Johnson (Sales)

 Oberon Capital (Joint Bookrunner)                                       Tel: +44 (0) 203 179 5300

 Mike Seabrook / Adam Pollock / Aimee McCusker                           corporatesales@oberoninvestments.com

                                                                       (mailto:corporatesales@oberoninvestments.com)

 Turner Pope Investments (TPI) Ltd (Joint Bookrunner)                    Tel: (0) 20 3657 0050

 Guy McDougall / Andy Thacker

 Walbrook PR Limited                                                     Tel: 020 7933 8780 or
 Anna Dunphy                                                             genincode@walbrookpr.com (mailto:genincode@walbrookpr.com)

 

Further information on the Company can be found on its website at
https://investors.genincode.com

 

The Company's LEI is 213800UX6TE7K65O2892.

 

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

 

Important Notices

 

This Announcement has been issued by, and is the sole responsibility, of the
Company.

 

This Announcement does not constitute, or form part of, a prospectus relating
to the Company, nor does it constitute or contain any invitation or offer to
any person, or any public offer, to subscribe for, purchase or otherwise
acquire any shares in the Company or advise persons to do so in any
jurisdiction, nor shall it, or any part of it form the basis of or be relied
on in connection with any contract or as an inducement to enter into any
contract or commitment with the Company. In particular, the New Ordinary
Shares have not been, and will not be, registered under the United States
Securities Act of 1933 as amended or qualified for sale under the laws of any
state of the United States or under the applicable laws of any of Canada,
Australia, Japan, or the Republic of South Africa, and may not be offered or
sold in the United States or to, or for the account or benefit of, US persons
(as such term is defined in Regulation S under the Securities Act) or to any
national, resident or citizen of Canada, Australia, Japan, or the Republic of
South Africa.

 

The distribution or transmission of this Announcement and the offering of the
New Ordinary Shares in certain jurisdictions other than the UK may be
restricted or prohibited by law or regulation. Persons distributing this
Announcement must satisfy themselves that it is lawful to do so. Any failure
to comply with these restrictions may constitute a violation of the securities
laws of any such jurisdiction. No action has been taken by the Company that
would permit an offering of such shares or possession or distribution of this
Announcement or any other offering or publicity material relating to such
shares in any jurisdiction where action for that purpose is required. Persons
into whose possession this Announcement comes are required by the Company to
inform themselves about, and to observe, such restrictions. In particular,
this Announcement may not be distributed, directly or indirectly, in or into a
Restricted Jurisdiction. Overseas Shareholders and any person (including,
without limitation, nominees and trustees), who have a contractual or other
legal obligation to forward this Announcement to a jurisdiction outside the UK
should seek appropriate advice before taking any action.

 

This Announcement includes "forward-looking statements" which includes all
statements other than statements of historical fact, including, without
limitation, those regarding the Company's financial position, business
strategy, plans and objectives of management for future operations, or any
statements preceded by, followed by or that include the words "targets",
"believes", "expects", "aims", "intends", "will", "may", "anticipates",
"would", "could" or similar expressions or negatives thereof. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors beyond the Company's control that could cause the
actual results, performance or achievements of the Group to be materially
different from future results, performance or achievements expressed or
implied by such forward-looking statements. Such forward-looking statements
are based on numerous assumptions regarding the Company's present and future
business strategies and the environment in which the Company will operate in
the future. These forward-looking statements speak only as at the date of this
Announcement. The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking statements
contained herein to reflect any change in the Company's expectations with
regard thereto or any change in events, conditions or circumstances on which
any such statements are based unless required to do so by applicable law or
the AIM Rules for Companies.

 

No statement in this Announcement is intended to be a profit forecast and no
statement in this Announcement should be interpreted to mean that earnings per
share of the Company for the current or future financial years would
necessarily match or exceed the historical published earnings per share of the
Company.

 

The New Ordinary Shares will not be admitted to trading on any stock exchange
other than the AIM market of the London Stock Exchange.

 

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) is incorporated into, or forms part of, this Announcement.

 

The price and value of securities can go down as well as up. Past performance
is not a guide to future performance.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBSGDDUXGDGLL



            Copyright 2019 Regulatory News Service, all rights reserved